Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Saved in:
| Title: | Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. |
|---|---|
| Authors: | Cole CB; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Morelli MP; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Fantini M; Precision Biologics, Inc, Bethesda, MD, USA. massimo.fantini@precision-biologics.com., Miettinen M; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Fetsch P; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Peer C; Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Figg WD; Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yin T; Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Houston N; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., McCoy A; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lipkowitz S; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zimmer A; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lee JM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Pavelova M; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Villanueva EN; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Trewhitt K; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Solarz BB; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Fergusson M; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mavroukakis SA; Precision Biologics, Inc, Bethesda, MD, USA., Zaki A; Precision Biologics, Inc, Bethesda, MD, USA., Tsang KY; Precision Biologics, Inc, Bethesda, MD, USA., Arlen PM; Precision Biologics, Inc, Bethesda, MD, USA., Annunziata CM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. annunzic@mail.nih.gov. |
| Source: | Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Apr 26; Vol. 42 (1), pp. 102. Date of Electronic Publication: 2023 Apr 26. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
